… can be categorized into subtypes that are associated with lower or higher risk for acute
myeloid leukemia transformation and that help with therapy selection. Patients with lower-risk …

… myelodysplastic syndrome and acute myeloid leukaemia related … myelodysplastic syndrome
and acute myeloid leukaemia in … of myelodysplastic syndrome and acute myeloid leukaemia …

… Myelodysplastic syndromes (MDS) are a family of myeloid cancers with diverse genotypes …
to acute myeloid leukaemia (AML). Some epidemiological data indicate that MDS incidence is …

… This study included patients age >2 years of age with a diagnosis of acute myelogenous
leukemia (AML), acute lymphoblastic leukemia, or myelodysplastic syndrome (MDS) who …

Myelodysplastic syndromes (MDS) are clonal … blood cytopaenias and progression to acute
myeloid leukaemia (AML) in one… 4, 5 Median age at diagnosis of MDS is w70 years and< 10% …

… acute myeloid leukaemia, mixed phenotype acute leukaemia, or high-risk myelodysplastic
syndrome … no previous potentially curative therapy for leukaemia. Patients received cladribine (…

… patients with acute myeloid leukaemia or myelodysplastic syndrome and Shwachman-Diamond
syndrome results from both high treatment related mortality and high disease resistance. …

… particularly myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). Families,
where typically two or more first- and/or second-degree relatives develop acute leukaemia (…

… history and treatment of MDS in order to benefit future … low-risk MDS patients who should
have pre-treatment variables … and cardiac disease remains the main non-leukaemic cause of …

… Measurable residual disease- guided treatment with azacitidine to prevent haematological
relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): …